nach oben

Erschienen in:

14.07.2017 | Original Article

Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies

verfasst von: Margrethe Raspotnig, Mette Haugen, Maria Thorsteinsdottir, Ingunn Stefansson, Helga B. Salvesen, Anette Storstein, Christian A. Vedeler

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Cerebellar degeneration-related protein 2 (CDR2) has been presumed to be the main antigen for the onconeural antibody Yo, which is strongly associated with ovarian cancer and paraneoplastic cerebellar degeneration (PCD). Recent data show that Yo antibodies also target the CDR2-like protein (CDR2L). We, therefore, examined the expression of CDR2 and CDR2L in ovarian cancer tissue from patients with and without Yo antibodies and from various other cancerous and normal human tissues.

Methods

Ovarian cancer tissue and serum samples from 16 patients were included in the study (four with anti-Yo and PCD, two with anti-Yo without PCD, five with only CDR2L antibodies, and five without onconeural antibodies). Clinical data were available for all patients. The human tissues were examined by western blot and immunohistochemistry using rabbit CDR2 and CDR2L antibodies.

Results

Ovarian cancers from all 16 patients expressed CDR2 and CDR2L proteins. Both proteins were also present in normal and cancer tissue from mammary tissue, kidney, ovary, prostate, and testis.

Conclusion

CDR2L is present in ovarian cancers from patients with and without Yo antibodies as was shown previously for CDR2. In addition, both CDR2 and CDR2L proteins are more widely expressed than previously thought, both in normal and cancerous tissues.

Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349(16):1543–1554CrossRefPubMed

Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G et al (2010) Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 67(3):330–335CrossRefPubMed

Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F et al (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 18(1):19CrossRefPubMed

Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB et al (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144(1):53–58CrossRefPubMedPubMedCentral

Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 42(10):1931–1937CrossRefPubMed

Dropcho EJ, Chen YT, Posner JB, Old LJ (1987) Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 84(13):4552–4556CrossRefPubMedPubMedCentral

Fathallah-Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM (1991) Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 88(8):3451–3454CrossRefPubMedPubMedCentral

Fathallah-Shaykh H, Finizio J, Posner JB (1992) Yo sera recognize a family of DNA binding proteins. Neurology 42(Suppl 3):415 (abstract)

Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB (1997) A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 17(4):1406–1415PubMed

10.

Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A et al (2013) CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS ONE 8(6):e66002CrossRefPubMedPubMedCentral

11.

Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA (2014) Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol 128(6):835–852CrossRefPubMedPubMedCentral

12.

Hwang JY, Lee J, Oh CK, Kang HW, Hwang IY, Um JW et al (2016) Proteolytic degradation and potential role of onconeural protein CDR2 in neurodegeneration. Cell Death Dis 7(6):e2240CrossRefPubMedPubMedCentral

13.

Totland C, Aarskog NK, Eichler TW, Haugen M, Nostbakken JK, Monstad SE et al (2011) CDR2 antigen and Yo antibodies. Cancer Immunol Immunother 60(2):283–289CrossRefPubMed

14.

Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA (2009) Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 58(11):1795–1800CrossRefPubMed

15.

Storstein A, Monstad SE, Haugen M, Mazengia K, Veltman D, Lohndal E et al (2011) Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol 232(1–2):166–170CrossRefPubMed

16.

Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) (2014) WHO classification of tumours of female reproductive organs, 4th edn. WHO Press, Geneva

17.

Prat J (2014) Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1–5CrossRefPubMed

18.

Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F et al (1990) Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 322(26):1844–1851CrossRefPubMed

19.

Darnell JC, Albert ML, Darnell RB (2000) Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 60(8):2136–2139PubMed

20.

Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S et al (2009) Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene 28(37):3274–3285CrossRefPubMed

21.

O’Donovan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB (2010) The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells. PLoS ONE 5(4):e10045CrossRefPubMedPubMedCentral

22.

Matschke J, Kromminga A, Erbersdobler A, Lamszus K, Anders S, Kofuncu E (2007) Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma. J Neurol Neurosurg Psychiatry 78(7):775–777CrossRefPubMed

23.

Rosine N, Chretien P, Adam C, Beaudonnet G, Not A, Drai J et al (2017) Expression of Yo antigen in a prostatic adenocarcinoma. Can J Neurol Sci 44(2):221–223CrossRefPubMed

24.

Storstein A, Raspotnig M, Vitaliani R, Giometto B, Graus F, Grisold W et al (2016) Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. J Neurol 263(5):1001–1007CrossRefPubMed

25.

Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52(12):715–738CrossRefPubMed

26.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998CrossRefPubMed

27.

Albert ML, Darnell RB (2004) Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 4(1):36–44CrossRefPubMed

28.

de Graaf MT, de Beukelaar JW, Haasnoot GW, Levering WH, Rogemond V, Didelot A et al (2010) HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol 226(1–2):147–149CrossRefPubMed

29.

Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191(3):423–434CrossRefPubMedPubMedCentral

30.

Yshii LM, Gebauer CM, Pignolet B, Mauré E, Quériault C, Pierau M et al (2016) CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139(11):2923–2934CrossRef

31.

Blachere NE, Orange DE, Santomasso BD, Doerner J, Foo PK, Herre M et al (2014) T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol 44(11):3240–3251CrossRefPubMedPubMedCentral

32.

Calzascia T, Loh JM, Di Berardino-Besson W, Masson F, Guillaume P, Burkhardt K et al (2008) Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes. Glia. 56(15):1625–1636CrossRefPubMed

33.

Prat J (2012) New insights into ovarian cancer pathology. Ann Oncol 23(Suppl 10):x111–x117CrossRefPubMed

34.

Bethesda MD (2016) SEER cancer stat facts: ovarian cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/ovary.html. Accessed 5 Nov 2016

35.

Monstad SE, Vedeler CA (2006) An immunoprecipitation assay for the detection of onconeural antibodies. Acta Neurol Scand Suppl 183:71–72CrossRefPubMed

36.

Storstein A, Monstad SE, Nakkestad HL, Husebye ES, Vedeler CA (2004) Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. J Neurol 251(2):197–203CrossRefPubMed

Titel: Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies
verfasst von: Margrethe Raspotnig
Mette Haugen
Maria Thorsteinsdottir
Ingunn Stefansson
Helga B. Salvesen
Anette Storstein
Christian A. Vedeler
Publikationsdatum: 14.07.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 11/2017
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2041-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy

“Tumor immunology meets oncology (TIMO) XII”, April 28th–30th 2016, Halle/Saale, Germany

Therapeutic antibodies against cancer stem cells: a promising approach

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer

IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model

Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie